mTOR kinase-dependent, but raptor-independent regulation of downstream signaling is important for cell cycle exit and myogenic differentiation

Cell Cycle

Volumn 13, Issue 16, 2014, Pages 2517-2525

  Pollard, Hilary J ^a   Willett, Mark ^a,b   Morley, Simon J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

4E BP1; C2C12; Initiation factor; Myoblasts; Raptor; Signaling; Translation

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; P70S6K PROTEIN; PROTEIN P70; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DEPLETION; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; INTRACELLULAR SIGNALING; MOUSE; MYOBLAST; MYOGENIC DIFFERENTIATION; NONHUMAN; PROTEIN PHOSPHORYLATION;

EID: 84907493896     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.941747     Document Type: Article

References (54)

1. Aoki MS, Miyabara EH, Soares AG, Saito ET, Moriscot AS. mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching. Cell Tissue Res 2006; 324:149-56; PMID: 16408196; http://dx.doi.org/10.1007/s00441-005-0081-4
2. Weintraub H. The myod family and myogenesis - redundancy, networks, and thresholds. Cell 1993; 75:1241-44; PMID: 8269506; http://dx.doi.org/10.1016/0092-8674(93)90610-3
3. Florini JR, Ewton DZ, Roof SL. Insulin-like growth factor-I stimulates terminal myogenic differentiation by induction of myogenin gene-expression. Mol Endocrinol 1991; 5:718-24; PMID: 1649394; http://dx.doi.org/10.1210/mend-5-5-718
4. Tollefsen SE, Lajara R, McCusker RH, Clemmons DR, Rotwein P. Insulin-like growth-factors (IGF) in muscle development - expression of IGF-I, the IGF-I receptor, and an IGF binding-protein during myoblast differentiation. J Biol Chem 1989; 264:13810-17; PMID: 2474537
5. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136:731-45; PMID: 19239892; http://dx.doi.org/10.1016/j.cell.2009.01.042
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID: 17613433; http://dx.doi.org/10.1016/j.ccr.2007.05.008
7. Laplante, M, Sabatini DM. mTOR signalling in growth control and disease. Cell 2012; 149:274-93; PMID: 22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
8. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 2003; 163:931-6; PMID: 14662739; http://dx.doi.org/10.1083/jcb.200307158
9. Park IH, Erbay E, Nuzzi P, Chen J. Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. Exp Cell Res 2005; 309:211-9; PMID: 15963500; http://dx.doi.org/10.1016/j.yexcr.2005.05.017
10. Shu LL, Zhang XW, Houghton PJ. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem 2002; 277:16726-32; PMID: 11875068; http://dx.doi.org/10.1074/jbc.M112285200
11. Park IH, Chen J. Mammalian target of rapamycin (mTOR) signalling is required for a late-stage fusion process during skeletal myotube maturation. J Biol Chem 2005; 280:32009-17; PMID: 16043480; http://dx.doi.org/10.1074/jbc.M506120200
12. Shu LL, and Houghton PJ. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol 2009; 29:4691-700; PMID: 19564418; http://dx.doi.org/10.1128/MCB.00764-09
13. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID: 21157483; http://dx.doi.org/10.1038/nrm3025
14. Gingras A-C, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel twostep mechanism. Genes Dev 1999; 13:1422-37; PMID: 10364159; http://dx.doi.org/10.1101/gad.13.11.1422
15. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45; PMID: 15314020; http://dx.doi.org/10.1101/gad.1212704
16. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-75; PMID: 12150925; http://dx.doi.org/10.1016/S0092-8674(02)00808-5
17. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 23:569-80; http://dx.doi.org/10.1016/j.cell.2005.10.024
18. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signalling to Akt-FOXO and PKC alpha, but not S6K1. Dev Cell 2006; 11:859-71; PMID: 17141160; http://dx.doi.org/10.1016/j.devcel.2006.10.007
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101; PMID: 15718470; http://dx.doi.org/10.1126/science.1106148
20. García-Martínez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoidinduced protein kinase 1 (SGK1) Biochem J 2008; 416:375-85; PMID: 18925875; http://dx.doi.org/10.1042/BJ20081668
21. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-28; PMID: 15467718; http://dx.doi.org/10.1038/ncb1183
22. Wang, X and Proud CG. mTORC1 signalling: what we still don't know. J Mol Cell Biol 2011; 3:206-20; PMID: 21138990; http://dx.doi.org/10.1093/jmcb/mjq038
23. Morley, SJ, Coldwell, M.J and Clemens, MJ. Initiation factor modifications in the preapoptotic phase. Cell Death Differ 2005; 12:571-84; PMID: 15900314; http://dx.doi.org/10.1038/sj.cdd.4401591
24. Jackson, RJ, Hellen, CUT and Pestova, TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010; 11:113-27; PMID: 20094052; http://dx.doi.org/10.1038/nrm2838
25. Ma, XM and Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nature reviews. Mol Cell Biol 2009; 10:307-18.
26. Willett M, Cowan JL, Vlasak M, Coldwell MJ, Morley SJ. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Cell Signal 2009; 21:1504-12; PMID: 19481146; http://dx.doi.org/10.1016/j.cellsig.2009.05.009
27. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747-59; PMID: 15797377; http://dx.doi.org/10.1016/j.cell.2004.12.040
28. Cowan JL, Morley SJ. The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complex. Eur J Biochem 2004; 271:3596-611; PMID: 15317596; http://dx.doi.org/10.1111/j.0014-2956.2004.04306.x
29. Coldwell MJ, Morley SJ. Specific isoforms of translation initiation factor 4GI show differences in translational activity. Mol Cell Biol 2006; 26:8448-60; PMID: 16982693; http://dx.doi.org/10.1128/MCB.01248-06
30. Morley SJ, Naegele S. Phosphorylation of initiation factor 4E is resistant to SB203580 in cells expressing a drug-resistant mutant of stress-activated protein kinase 2a/p38. Cell Signal 2003; 215:741-9; http://dx.doi.org/10.1016/S0898-6568(03)00008-1
31. García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009; 421:29-42; PMID: 19402821; http://dx.doi.org/10.1042/BJ20090489
32. Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000; 2:893-8; PMID: 11146653; http://dx.doi.org/10.1038/35046542
33. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152-59; PMID: 15604286; http://dx.doi.org/10.1158/0008-5472.CAN-04-2727
34. Farkas T, Daugaard M, Jäättelä M. Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy. J Biol Chem 2011; 286:38904-12; PMID: 21930714; http://dx.doi.org/10.1074/jbc.M111.269134
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101; PMID: 15718470; http://dx.doi.org/10.1126/science.1106148
36. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68; PMID: 16603397; http://dx.doi.org/10.1016/j.molcel.2006.03.029
37. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4:1533-40; PMID: 16227402; http://dx.doi.org/10.1158/1535-7163.MCT-05-0068
38. Naegele S, Morley SJ. Molecular cross-talk between MEK1/2 and mTOR signalling during recovery of 293 cells from hypertonic stress. J Biol Chem 2008; 279:46023-34; http://dx.doi.org/10.1074/jbc.M404945200
39. Caron S, Charon M, Cramer E, Sonenberg N, Dusanter-Fourt I. Selective modification of eukaryotic initiation factor 4F (eIF4F) at the onset of cell differentiation: recruitment of eIF4GII and longlasting phosphorylation of eIF4E. Mol Cell Biol 2004; 24:4920-8; PMID: 15143184; http://dx.doi.org/10.1128/MCB.24.11.4920-4928.2004
40. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci. USA 2008; 105,17414-9; http://dx.doi.org/10.1073/pnas.0809136105
41. Ching JK, Luebbert SH, Collins RL 4th, Zhang Z, Marupudi N, Banerjee S, Hurd RD, Ralston L, Fisher JS. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle. Exp Physiol 2013; 98:526-35; PMID: 22941977; http://dx.doi.org/10.1113/expphysiol.2012.066357
42. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114:1618-27; PMID: 19458359; http://dx.doi.org/10.1182/blood-2008-10-184515
43. Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012; 120:3491-500; PMID: 22955922; http://dx.doi.org/10.1182/blood-2012-02-412643
44. Fuhler GM, Tyl MR, Olthof SG, Lyndsay Drayer A, Blom N, Vellenga E. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells. Eur J Haematol 2009; 83:235-45; PMID: 19341427; http://dx.doi.org/10.1111/j.1600-0609.2009.01263.x
45. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25:903-15; PMID: 17386266; http://dx.doi.org/10.1016/j.molcel.2007.03.003
46. Kazi AA, Lang CH. PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts. Mol Med 2010; 9-10:359-71.
47. Zhang Y, and Zheng XFS. mTOR-independent 4EBP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012; 11:594-603; PMID: 22262166; http://dx.doi.org/10.4161/cc.11.3.19096
48. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V and Foster DA. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10:3948-56; PMID: 22071574; http://dx.doi.org/10.4161/cc.10.22.18124
49. Erbay E, Chen J. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J Biol Chem 2001; 276: 36079-82; PMID: 11500483; http://dx.doi.org/10.1074/jbc.C100406200
50. Chao SK, Horwitz SB1, and McDaid HM. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget 2011; 2:89-98; PMID: 21399233
51. Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013; 18:698-711; PMID: 24206664; http://dx.doi.org/10.1016/j.cmet.2013.10.001
52. Bentzinger CF1, Romanino K, Cloëtta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Rüegg MA. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 2008; 8:411-24; PMID: 19046572; http://dx.doi.org/10.1016/j.cmet.2008.10.002
53. Csibi A, Cornille K, Leibovitch MP, Poupon A, Tintignac LA, Sanchez AM, Leibovitch SA. The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse. PLoS One 2010; 5(2):e8994; PMID: 20126553; http://dx.doi.org/10.1371/journal.pone.0008994
54. Martineau Y, Wang X, Alain T, Petroulakis E, Shahbazian D, Fabre B, Bousquet-Dubouch MP, Monsarrat B, Pyronnet S, Sonenberg N. Control of Paip1-eIF3 interaction by amino acids through S6 Kinase. Mol Cell Biol 2014; 34,1046-53; PMID: 24396066; http://dx.doi.org/10.1128/MCB.01079-13